Glucocorticoids act in the dorsal hindbrain to modulate baroreflex control of heart rate

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 290, Issue 4, 2006, Pages

  Bechtold, Andrea G ^a   Scheuer, Deborah A ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Brain; Corticosterone; Glucocorticoid receptors; Nucleus of the solitary tract; Stress

Indexed keywords

CORTICOSTERONE; GLUCOCORTICOID; SILASTIC;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; HEART RATE; KIDNEY NERVE; MALE; NERVE CONDUCTION; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; RHOMBENCEPHALON; SYMPATHETIC NERVE;

ANIMALS; ARTERIES; BAROREFLEX; CARRIER PROTEINS; CATHETERS, INDWELLING; CONSCIOUSNESS; DIMETHYLPOLYSILOXANES; GLUCOCORTICOIDS; HEART RATE; MALE; NEUROPEPTIDES; PRESSORECEPTORS; RATS; RATS, SPRAGUE-DAWLEY; RHOMBENCEPHALON; SILICONES;

EID: 33646473541     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00345.2005     Document Type: Article

References (60)

1. Akana SF, Scribner KA, Bradbury MJ, Strack AM, Walker CD, and Dallman MF. Feedback sensitivity of the rat hypothalamo-pituitaryadrenal axis and its capacity to adjust to exogenous corticosterone. Endocrinology 131: 585-594, 1992.
2. Alvarez GE, Davy BM, Ballard TP, Beske SD, and Davy KP. Weight loss increases cardiovagal baroreflex function in obese young and older men. Am J Physiol Endocrinol Metab 289: E665-E669, 2005.
3. Barrett CJ and Malpas SC. Problems, possibilities, and pitfalls in studying the arterial baroreflexes' influence over long-term control of blood pressure. Am J Physiol Regul Integr Comp Physiol 288: R837-R845, 2005.
4. Bing SH, Wang HL, and Leenen FHH. Chronic central infusion of aldoseterone leads to sympathetic hyperactivity and hypertension in Dahl S but not Dahl R rats. Am J Physiol Heart Circ Physiol 288: H517-H524, 2005.
5. Bradbury MJ, Akana SF, and Dallman MF. Roles of type I and II corticosteroid receptors in regulation of basal activity in the hypothalamopituitary-adrenal axis during the diurnal trough and peak: evidence for a nonadditive effect of combined receptor occupation. Endocrinology 134: 1286-1296, 1994.
6. Brooks VL, Ell KR, and Wright RM. Pressure-independent resetting produced by chronic infusion of angiotensin II in rabbits. Am J Physiol Heart Circ Physiol 265: H1275-H1282, 1993.
7. Cintra A, Zoli M, Rosen L, Agnati F, Okret S, Wikstrom AC, Gustafsson JA, and Fuxe K. Mapping and computer assisted morphometry and microdensitometry of glucocorticoid receptor immunoreactive neurons and glial cells in the rat central nervous system. Neuroscience 62: 843-897, 1994.
8. Clapham JC and Turner NC. Effects of the glucocorticoid II receptor antagonist mifepristone on hypertension in the obese Zucker Rat. J Pharmacol Exp Ther 282: 1503-1508, 1997.
9. de Kloet ER, van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, and de Jong W. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 57: 1329-1336, 2000.
10. de Kloet RE. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 12: 95-164, 1991.
11. Dorward PK, Andresen MC, Burke SL, Oliver JR, and Korner PI. Rapid resetting of the aortic baroreceptors in the rabbit and its implication for short-term and longer term reflex control. Circ Res 50: 428-439, 1982.
12. Gardiner SM and Bennett T. Post-adrenalectomy hypotension in rats: absence of baroreflex resetting or effects of naloxone. Clin Sci (Colch) 64: 371-376, 1983.
13. Girod JP and Brotman DJ. Does altered glucocorticoid homeostasis increase cardiovascular disease risk? Cardiovasc Res 64: 217-226, 2004.
14. Goldstein DS. Arterial baroreflex sensitivity, plasma catecholamines, and pressor responsiveness in essential hypertension. Circulation 68: 234-240, 1983.
15. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, and Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol Endocrinol Metab 258: E649-E653, 1990.
16. Grippo AJ, Moffitt JA, and Johnson AK. Cardiovascular alterations and autonomic imbalance in an experimental model of depression. Am J Physiol Regul Integr Comp Physiol 282: R1333-R1341, 2002.
17. Harfstrand A, Fuxe K, Cintra A, Agnati LF, Zini I, Wikstrom AC, Okret S, Yu ZY, Goldstein M, Steinbusch H, Verhofstad A, and Gustafsson JA. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc Natl Acad Sci USA 83: 9779-9783, 1986.
18. Hashimoto K, Makino S, Hirasawa R, Takao T, Sugawara M, Murakami K, Ono K, and Ota Z. Abnormalities in the hypothalamopituitary-adrenal axis in spontaneously hypertensive rats during development of hypertension. Endocrinology 125: 1161-1167, 1989.
19. Hohnloser SH, Klingenheben T, van de Loo A, Hablawetz E, Just H, and Schwartz PJ. Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation. Circulation 89: 1068-1073, 1994.
20. Huerta C, Lanes SF, and Rodriguez LAG. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 16: 360-366, 2005.
21. Izzo JI and Black HR. Hypertension Primer (3rd ed.). Philadelphia, PA: Lippincott Williams & Wilkens, 2003.
22. Kent BB, Drane JW, Blumenstein B, and Manning JW. A mathematical model to assess changes in the baroreceptor reflex. Cardiology 57: 295-310, 1972.
23. Lanfranchi PA and Somers VK. Arterial baroreflex function and cardiovascular variability: interactions and implications. Am J Physiol Regul Integr Comp Physiol 283: R815-R826, 2002.
24. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, Nohara R, Bigger JTJ, Camm AJ, and Schwartz PJ. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 103: 2072-2076, 2001.
25. Lin RCY, Wang XL, and Morris BJ. Association of coronary artery disease with glucocorticoid receptor N363S variant. Hypertension 41: 404-407, 2003.
26. Lin RCY, Wang YSW, and Morris BJ. Association and linkage analyses of glucocorticoid receptor gene markers in essential hypertension. Hypertension 34: 1186-1192, 1999.
27. Litchfield WR, Hunt SC, Jeunemaitire X, Fisher ND, Hopkins PN, Williams RR, Corvol P, and Williams GH. Increased urinary free cortisol: a potential intermediate phenotype of essential hypertension. Hypertension 31: 569-574, 1998.
28. Loewy AD and Spyer KM. Vagal preganglionic neurons In: Central Regulation of Autonomic Function, edited by Loewy AD and Spyer KM. New York: Oxford Univ, 1990, p. 68-87.
29. Lohmeier TE, Hildebrandt DA, Warren S, May PJ, and Cunningham JT. Recent insights into the interactions between the baroreflex and kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol 288: R828-R836, 2005.
30. Meyer JS, Micco DJ, Stephenson BS, Krey LC, and McEwen BS. Subcutaneous implantation method for chronic glucocorticoid replacement therapy. Physiol Behav 22: 867-870, 1979.
31. Mifflin SW and Felder RB. Synaptic mechanisms regulating cardiovascular afferent inputs to solitary tract nucleus. Am J Physiol Heart Circ Physiol 259: H653-H661, 1990.
32. Osborn JW, Jacob F, and Guzman P. A neural set point for the long-term control of arterial pressure: beyond the arterial baroreceptor reflex. Am J Physiol Regul Integr Comp Physiol 288: R846-R855, 2005.
33. Ottenweller JE, Servatius RJ, and Natelson BH. Repeated stress persistently elevates morning, but not evening, plasma corticosterone levels in male rats. Physiol Behav 55: 337-340, 1994.
34. Rosmond R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obesity Res 10: 1078-1086, 2002.
35. Rosmond R, Chagnon YC, Holm G, Chagnon M, Perusse L, Lindell K, Carlsson B, Bouchard C, and Bjorntorp P. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin and dysregulation of the hypothalamic-pituitary-adrenal axis. Obesity Res 8: 211-218, 2000.
36. Sanya EO, Brown CM, Dutsch M, Zikeli U, Neundorfer B, and Hilz MJ. Impaired cardiovagal and vasomotor responses to baroreceptor stimulation in type II diabetes mellitus. Eur J Clin Invest 33: 582-588, 2003.
37. Scheuer DA and Bechtold AG. Glucocorticoids modulate baroreflex control of heart rate in conscious normotensive rats. Am J Physiol Regul Integr Comp Physiol 282: R475-R483, 2002.
38. Scheuer DA, Bechtold AG, Shank SS, and Akana SF. Glucocorticoids act in the dorsal hindbrain to increase arterial pressure. Am J Physiol Heart Circ Physiol 286: H458-H467, 2004.
39. Scheuer DA and Mifflin SW. Chronic corticosterone treatment increases myocardial infarct size in rats with ischemia reperfusion injury. Am J Physiol Regul Integr Comp Physiol 272: R2017-R2024, 1997.
40. Scheuer DA and Mifflin SW. Glucocorticoids modulate baroreflex control of renal sympathetic nerve activity. Am J Physiol Regul Integr Comp Physiol 280: R1440-R1449, 2001.
41. Schimmer BP and Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones In: Goodman and Gilman's The Pharmacological Basis of Therapeutics (10th ed.), edited by Hardman JG, Limbird LE, and Gilman AG. New York: McGraw-Hill, 2001, p. 1649-1677.
42. Segar JL, Bedell KA, and Smith OJ. Glucocorticoid modulation of cardiovascular and autonomic function in preterm lambs: role of ANG II. Am J Physiol Regul Integr Comp Physiol 280: R646-R654, 2001.
43. Segar JL, Lumbers ER, Nuyt AM, Smith OJ, and Robillard JE. Effect of antenatal glucocorticoids on sympathetic nerve activity at birth in preterm sheep. Am J Physiol Regul Integr Comp Physiol 274: R160-R167, 1998.
44. Segar JL, Van Natta T, and Smith OJ. Effects of fetal ovine adrenalectomy on sympathetic and baroreflex responses at birth. Am J Physiol Regul Integr Comp Physiol 283: R460-R467, 2002.
45. Shelat SG, King JL, Flanagan-Cato LM, and Fluharty SJ. Mineralocorticoids and glucocorticoids cooperatively increase salt intake and angiotensin II receptor binding in rat brain. Neuroendocrinology 69: 339-351, 1999.
46. Sholter DE and Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 16: 505-511, 2000.
47. Soro A, Ingram MC, Tonolo G, Glorioso N, and Fraser R. Mildly raised corticosterone excretion rates in patients with essential hypertension. J Hum Hypertens 9: 391-393, 1995.
48. Sun M-K. Central neural organization and control of sympathetic nervous system in mammals. Prog Neurobiol 47: 157-233, 1995.
49. Takahashi H, Takeda K, Ashizawa H, Inoue A, Yoneda S, Yoshimura M, and Ijichi H. Centrally induced cardiovascular and sympathetic responses to hydrocortisone in rats. Am J Physiol Heart Circ Physiol 245: H1013-H1018, 1983.
50. Thrasher TN. Baroreceptors, baroreceptor unloading, and the long-term control of blood pressure. Am J Physiol Regul Integr Comp Physiol 288: R819-R827, 2005.
51. Tonolo G, Soro A, Madeddu P, Troffa C, Melis MG, Patteri G, Pinna Parpaglia P, Sabino G, Maioli M, and Glorioso N. Effect of chronic intracerebroventricular dexamethasone on blood pressure in normotensive rats. Am J Physiol Endocrinol Metab 264: E843-E847, 1993.
52. Ullian ME. The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res 41: 55-64, 1999.
53. van Acker SA, Fluttert MF, Sibug RM, and de Kloet ER. Intracerebroventricular administration of a glucocorticoid receptor antagonist enhances the cardiovascular responses to brief restraint. Eur J Pharmacol 430: 87-91, 2001.
54. van den Berg DTWM, De Kloet ER, van Dijken HH, and de Jong W. Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure. Endocrinology 126: 118-124, 1990.
55. Wake DJ and Walker BR. 11 Beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol Cell Endocrinol 215: 44-54, 2004.
56. Walker B, Stewart PM, Shackleton CH, Padfield PL, and Edwards CRW. Deficient inactivation of cortisol by 11-beta-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol (Oxf) 39: 221-227, 1993.
57. Walker BR, Best R, Shackleton CHL, Padfield PL, and Edwards CRW. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 27: 190-196, 1996.
58. Wei L, MacDonald TM, and Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141: 764-770, 2004.
59. Whitworth JA, Mangos GJ, and Kelley JJ. Cushing, cortisol and cardiovascular disease. Hypertension 36: 912-916, 2000.
60. Yagil Y, Levin M, and Krakoff LR. Effect of glucocorticoid deficiency on arterial pressure in conscious spontaneously hypertensive rats. Hypertension 2: 99-104, 1989.